Brokerages Set GoodRx Holdings, Inc. (NASDAQ:GDRX) Target Price at $8.37

GoodRx Holdings, Inc. (NASDAQ:GDRX) has been given an average rating of “Moderate Buy” by the sixteen analysts that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation, nine have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $8.37.

A number of research analysts recently issued reports on the company. Citigroup reduced their price objective on GoodRx from $10.00 to $7.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. Morgan Stanley reduced their price target on shares of GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a report on Tuesday, December 17th. Barclays cut their price objective on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a research report on Monday, November 11th. Finally, Mizuho initiated coverage on shares of GoodRx in a research note on Wednesday, December 4th. They set a “neutral” rating and a $5.00 target price for the company.

GoodRx Price Performance

GDRX opened at $4.52 on Friday. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70. The company’s 50-day moving average price is $5.14 and its 200 day moving average price is $6.86. GoodRx has a fifty-two week low of $4.09 and a fifty-two week high of $9.26. The firm has a market cap of $1.72 billion, a price-to-earnings ratio of -150.67, a price-to-earnings-growth ratio of 3.54 and a beta of 1.29.

Institutional Trading of GoodRx

A number of hedge funds have recently modified their holdings of the company. Liontrust Investment Partners LLP bought a new position in GoodRx during the second quarter worth about $520,000. Legato Capital Management LLC bought a new position in shares of GoodRx during the 2nd quarter valued at about $805,000. Picton Mahoney Asset Management grew its position in shares of GoodRx by 24.3% in the 2nd quarter. Picton Mahoney Asset Management now owns 607,090 shares of the company’s stock valued at $4,736,000 after purchasing an additional 118,703 shares during the period. ClariVest Asset Management LLC increased its stake in GoodRx by 27.4% during the 2nd quarter. ClariVest Asset Management LLC now owns 195,722 shares of the company’s stock worth $1,527,000 after purchasing an additional 42,097 shares in the last quarter. Finally, American Century Companies Inc. bought a new stake in GoodRx during the 2nd quarter worth approximately $18,183,000. 63.77% of the stock is currently owned by institutional investors and hedge funds.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.